Quotient Therapeutics

What Quotient Therapeutics does

Quotient Therapeutics is a somatic genomics platform company founded in 2022 by Flagship Pioneering, headquartered in Cambridge, MA with a genomics hub at Chesterford Research Park near Cambridge, UK. The company's core product is a proprietary platform that combines single-molecule genome sequencing — internally branded as Nanorate — with AI and computational biology to study naturally occurring genetic variation in individual cells of patient tissue. By analyzing somatic mutations that accumulate within cells over a lifetime, Quotient aims to identify disease-causal genes that traditional germline genetic approaches miss, claiming the ability to surface significant disease-driving or protecting mutations from as few as 10–30 patients per study.

The platform is delivered almost exclusively through multi-year, enterprise-scale research collaborations with major pharmaceutical companies, who pay upfront fees and milestone payments for access to Quotient's somatic genomics capabilities in specific therapeutic areas. Disclosed partnerships include a $20M upfront / up to $2.2B collaboration with Merck in inflammatory bowel disease, a cardiovascular and renal program with Pfizer, feasibility agreements with GSK in COPD, IPF, and MASH, and an extended partnership with Ipsen in ultra-rare disease. Revenue mechanics are milestone-weighted, with development, regulatory, and commercial milestones representing the largest potential value components. The customer base is a small set of large-cap pharma counterparties, and several deals flow through Flagship Pioneering's pre-existing framework agreements with Pfizer and GSK.

Quotient is led by a team that combines academic co-founders from the Wellcome Sanger Institute and UT Southwestern (including Sir Mike Stratton, Peter Campbell, and Inigo Martincorena) with experienced biotech operators such as CEO Rahul Kakkar (previously CEO of Pandion, sold to Merck for $1.85B, and founder/CMO of Corvidia, sold to Novo Nordisk for $2.1B), CDO Andrew Bayliffe (ex-GSK), and CFO Susan Keefe. The company has 11–50 employees and has not disclosed product revenue; the Flagship-originated $50M initial commitment in November 2023 remains the only disclosed funding event to date.

Name

Quotient Therapeutics

Legal name

Quotient Therapeutics, Inc.

Website

https://quotient-tx.com

Company type

Private

Founded year

2022

Operating status

Operating

Headcount range

51–100 employees

Short description

Quotient Therapeutics is a Flagship Pioneering-backed somatic genomics platform company that partners with major pharmaceutical companies to discover genetically validated drug targets using proprietary single-molecule sequencing and AI, requiring only 10–30 patients per study. Active collaborations include Merck, Pfizer, GSK, and Ipsen.

Ownership category

akta.pro rank

Product category

Drug Target Discovery and Somatic Genomics Biotechnology

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)

akta.pro secondary industry

AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE)

Keywords

• Somatic genomics
• Drug target discovery
• Genome sequencing technology
• Pharmaceutical research collaborations
• Genetically validated therapeutics

Headquarters

HQ city

London

HQ country

United Kingdom

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Research Collaboration Upfront Payments: Pharmaceutical partners pay upfront fees to access Quotient's somatic genomics platform for drug target discovery in specific disease areas. Example: $20 million upfront from Merck for IBD collaboration.
2. Milestone Payments: Quotient earns development, regulatory, and commercial milestone payments as partnered programs progress. Example: up to $2.2 billion total deal value with Merck including milestones.
3. Initial Funding: Flagship Pioneering made an initial commitment of $50 million to advance development of the company's platform and pursue a pipeline of medicines.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Core offering

Quotient Therapeutics operates a proprietary Somatic Genomics Platform that uses single-molecule genome sequencing combined with AI and computational biology to identify somatic mutations in patient tissue that cause or protect against disease. The company translates these discoveries into genetically-validated drug targets and partners with major pharmaceutical companies on multi-year research collaborations and milestone-based development programs.

Product overview

Quotient Therapeutics operates as a platform company offering a unified Somatic Genomics Platform that integrates proprietary genome sequencing technology with AI and computational biology tools. The platform enables researchers to study naturally accumulated genetic mutations in patient tissue to identify disease-causal drug targets across multiple therapeutic areas including autoimmune, cardiometabolic, oncology, and rare diseases. The company's core technology is the Somatic Genomics Platform, which serves as the foundation for both internal drug discovery programs and external partnerships with pharmaceutical companies.

Differentiator

Problem solved

Functional benefit

Products and services

• Somatic Genomics Platform Proprietary platform that uses single molecule genome sequencing and AI-driven computational biology to identify somatic mutations in patient tissue that cause or protect against disease, enabling discovery of genetically-validated drug targets for pharmaceutical partners.
• Industrialized Somatic Genomics Technology

Quantifiable outcome

• Requires only 10-30 patients per study to find significant disease-driving mutations
• +1 more outcomes

Named customers3 records

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Four partnerships are on record, tiered core and minor.

• Merck (MSD)coreStrategic or Co-development Partner · 24 March 2026Multi-year research collaboration to discover novel drug targets in inflammatory bowel disease (IBD) using Quotient's somatic genomics platform. Quotient receives $20 million upfront and up to $2.2 billion in development, regulatory, and commercial milestones. The partnership leverages Quotient's platform to analyze patient tissue for somatic mutations that cause or protect from disease.
• IpsenminorStrategic or Co-development Partner · 27 February 2026Extended partnership focused on ultra-rare disease therapy development using Quotient's somatic genomics approach.
• GSKcoreStrategic or Co-development Partner · 20 November 2025Feasibility agreements under the Flagship-GSK framework collaboration to discover and validate novel treatments for COPD, idiopathic pulmonary fibrosis (IPF), and metabolic dysfunction-associated steatohepatitis (MASH). If GSK elects to progress, programs advance through preclinical activities with exclusive option for clinical studies.
• PfizercoreStrategic or Co-development Partner · 28 August 2024Research collaboration under Flagship's strategic partnership with Pfizer to discover new targets for cardiovascular and renal diseases. Quotient and Pioneering Medicines jointly conduct research analyzing somatic mutations in diseased patient tissue to inform development of transformative therapies.

Scale indicators3 records

Recent moves8 records

Expansion highlights5 records

Direct peers

• Generate Biomedicines: Flagship Pioneering sister company combining generative AI with biology to design novel protein therapeutics. Comparable as a Flagship-originated platform biotech that pairs proprietary computational technology with multi-target pharma partnerships across multiple therapeutic areas.
• Insitro: AI-driven drug discovery platform combining machine learning with high-throughput biology to identify novel targets. Comparable as a platform company monetizing proprietary data and AI capabilities through pharma partnerships and internal pipeline programs.
• Maze Therapeutics: Genetics-driven drug discovery company using functional genomics and variant interpretation to identify causal targets. Comparable as a platform translating human genetic variation into validated drug targets through pharma partnerships and an internal pipeline.
• Recursion Pharmaceuticals: AI-enabled drug discovery platform using high-throughput biology, imaging, and machine learning to identify targets and advance small molecules. Comparable as a publicly-listed platform company monetizing proprietary data and AI through partnerships and internal programs.
• Isomorphic Labs: Alphabet/DeepMind spin-off applying AlphaFold-derived AI to drug discovery and target identification. Comparable as an AI-first platform pursuing both partnered programs and internal pipeline assets across multiple therapeutic areas.
• Xaira Therapeutics: AI-native drug discovery company founded in 2023 with significant capital, applying foundation models to biology and target ID. Comparable as a recent, well-capitalized entrant into AI-enabled target discovery pursuing pharma partnerships and internal development.
• Tessera Therapeutics: Flagship Pioneering company developing gene writing technology with both internal programs and pharma partnerships. Comparable as a Flagship-originated platform company pairing novel molecular technology with multi-billion-dollar pharma collaborations.
• Atomwise: AI-driven small molecule discovery company using structure-based design and partnerships with pharma. Comparable as an AI-first platform company commercializing target and molecule discovery through enterprise collaborations with major pharma.

Broad incumbents

• Schrödinger: Established computational chemistry and predictive modeling platform with both software and internal drug discovery programs. Comparable as a broader computational drug discovery incumbent with mature pharma relationships, but less focused on omics-driven target identification.

Emerging players

• Owkin: AI-biomedicine company combining multimodal patient data, including genomics, with machine learning to discover targets and develop diagnostics. Comparable as an emerging player applying AI to omics-driven target identification, with a stronger diagnostics orientation than Quotient.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xtwitter.com/QuotientTx
• LinkedInlinkedin.com/company/quotient-therapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles13 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Quotient Therapeutics